Acrux begins anti-nausea trial
Wednesday, 02 March, 2005
Acrux (ASX:ACR) has commenced dosing in a Phase I clinical trial utilising its MDTS transdermal spray to deliver anti-nausea drug granisetron. The pharmacokinetics trial will compare absorption of the drug, which is used to treat nausea in chemotherapy patients, against that of an oral formulation in six healthy volunteers.
"Prevention of nausea during chemotherapy with a product that does not require injections or tablets would help minimise distress for cancer patients," said Acrux CEO Igor Gonda. Brisbane-based CRO Q-Pharm is conducting the trial in its clinical trials facilities at the Royal Brisbane Hospital for Acrux subsidiary Acrux DDS.
Keto diet leads to health benefits in bipolar patients
A ketogenic diet may improve brain metabolism in individuals with a bipolar disorder diagnosis,...
Surface coating could prevent blood clots in medical implants
Zwitterions — a common macromolecule found in human cells — are being used to create...
mRNA successfully delivered through blood–brain barrier
Getting mRNA into the brain could allow scientists to instruct brain cells to produce therapeutic...
